SCHEMBL5165352

SCHEMBL5165352

Cc1ccc(N(C)C(=O)c2c(O)c3c(Cl)cccc3n(C)c2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.58
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
PGR P06401 1/20 0.57
GPBAR1 Q8TDU6 6/20 0.44
MAPT P10636 1/20 0.42
SRC P12931 1/20 0.41
EGFR P00533 1/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 2/20 0.37
PABPC1 P11940 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
RORC P51449 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165280 0.93 HDAC4 (0.58) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL6996393 0.92 MEN1 (0.68) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL7561993 0.90 KMT2A (0.60) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL7236279 0.89 HDAC4 (0.62) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL7202009 0.86 HDAC4 (0.58) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL7538318 0.85 HDAC4 (0.43) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL5166744 0.85 HDAC4 (0.57) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL19398184 0.84 HDAC4 (0.79) HDAC4MEN1KMT2APGRGPBAR1
SCHEMBL7200053 0.82 HDAC4 (0.54) HDAC4MEN1KMT2APGRMAPT
SCHEMBL16248354 0.82 HDAC4 (0.41) HDAC4MEN1KMT2APGRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP claimed
US-20020173520-A1 Quinoline derivatives ACTIVE BIOTECH AB (SE) 2002-11-21 US claimed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US claimed
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP disclosed
US-20020173520-A1 Quinoline derivatives ACTIVE BIOTECH AB (SE) 2002-11-21 US disclosed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173520-A1 Quinoline derivatives CYP4F3, IRF3, CXCR3 HDAC4 2957/4885MEN1 1051/4885KMT2A 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.